Drugs / tolerogenic dendritic cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02618902 | May 2017 → Feb 2022 | multiple sclerosis | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1 | NCT03337165 | Dec 2016 → May 2019 | rheumatoid arthritis | Russian Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02622763 | Nov 2015 → May 2019 | Crohn disease | Fundacion Clinic per a la Recerca Biomédica | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT07020715 | Jul 2026 → Sep 2029 expected | multiple sclerosis | University Hospital, Antwerp | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06715605 | Apr 2025 | multiple sclerosis | University Hospital, Antwerp | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tolerogenic dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06715605 ↗ |
| Known as | tolDC | “autologous tolerogenic dendritic cells (tolDC) is a promising approach.” PMID 31501122 ↗ Sep 20191“Tolerogenic dendritic cells (tolDC)” NCT07020715 ↗ |
| Action | Restore | “Specifically restoring immune tolerance towards myelin antigens may provide an attractive alternative.” PMID 31501122 ↗ Sep 2019 |
| Modality | Cell therapy | “autologous tolerogenic dendritic cells (tolDC)” PMID 31501122 ↗ Sep 2019 |
| Route | Other | “Intralesional administration” NCT02622763 ↗ |